



ACC Latin America
Conference 2017



MEXICO CITY
JUNE 22 – 24, 2017

GLOBAL EXPERTS, LOCAL LEARNING



ACC Latin America
Conference 2017

CASE PRESENTATION

Dr Eduardo F. Mele, FACC, FESC

Governor Argentina Chapter

Past President Argentine Society of Cardiology

Sanatorio Güemes

Buenos Aires



F.C. Male 59 y old

T2DBM treated with metphormin

No other medication.

Asyptomatic until the onset of his current disease

Works in a restaurant as a waiter

Two months ago effort dyspnea that began in


Functional Class II and progressed to III



Visit ER: asymptomatic at rest,
BP 120/80, HR85 bpm, regular
Peripheral oedema
Rales in both lungs. S3

Treated with Furosemide and Nitroglycerin IV

Admitted in Cardiology asymptomatic,
began ACE inhibitors and espironolactone



Echocardiography LV 53/42. Fey 35%
septal, septo apical and lateroapical akinesia



ACC Latin America
Conference 2017

1\32

CAPARROZ FRANCISCO

ID 3618638-7 \ M

DOB Adulto

Acc. #3079036

01/08/2016

St.ID 7933

PHILIPS CAPARROZ, FRANCISCO

16-08-01-161243

Philips Healthcare

MI 1,4

TIS 0,9

01/08/2016

04:23:39 p.m

Philips Healthcare

SE. #1

US

2D

H3

Gan. 54

232dB/C5

D/2/0

AOP

P

Im. #15
16:23:40 p.m.

Zoom: 99%

PS:

VOI:

WC: 128,00

WW: 256,00

P
1,9 3,8
R

ORIGINAL\PRIMARY\INTRACARDIAC\0001

Free Form

BPM:



1x1

CAPARROZ FRANCISCO

ID 3618638-7 \ M

DOB

Acc. #3079036

01/08/2016

St.ID 7933

PHILIPS CAPARROZ, FRANCISCO

16-08-01-161243

Philips Healthcare

MI 1,4

01/08/2016

Philips Healthcare

TIS 0,9

04:20:06 p.m

SE. #1

US

Adulto

64-2

30Hz

19cm

FE(MDD-ps4)

0,358

+ VTS(MDD-ps4)

113 cm3

AVIts ap4

34,6 cm2

AVIts apical

34,6 cm2

LVIts apical

2,97 cm

2D


H3

Gan. 54

232dB/C5

D/2/0

Im. #9
16:20:06 p.m.



Zoom: 104%

PS:

VOI:

WC: 128,00

WW: 256,00

G
P R
1,9 3,8

ORIGINAL\PRIMARY\INTRACARDIAC\0001

Free Form

BPM:



The patient did well, oedema and pulmonary rales disappeared. Lost 5 Kgm in 6 days

What's next:

Stress scintigraphy?


Stress echo?


MRI?


Coronary angiography?



ACC Latin America
Conference 2017









CABG was performed LIMA to LAD, SVG to circumphlex, RCA an 1st diagonal branch

No posoperative complications

Treated with beta blockers, aspirin, ACE inhibitors, metphormin and high dose statins

6 months later asymptomatic in Functional Class 1



Echo EF 40,5 %

1\173

CAPARROZ FRANCISCO

ID 3618638-7 \ M

DOB

Acc. #3144241

04/11/2016

St.ID 1272

PHILIPS CAPARROZ

16-11-04-104703

Philips Healthcare

MI 1,4

TIS 0,6

04/11/2016

10:55:55 a.m

Philips Healthcare

SE. #1

US

ADULTO GR.

S3-1

29Hz

19cm

2D

H3

Gan. 37

232dB/C5

D/2/0

Im. #10

10:56:02 a.m.

Zoom: 99%

PS:

VOI:

WC: 128,00

WW: 256,00

P
1,7 3,4
R

ORIGINAL\PRIMARY\INTRACARDIAC\0001

Free Form

BPM:



This image is not for diagnostic purposes

1/1

CAPARROZ FRANCISCO

ID 3618638-7 \ M

DOB ADULTO GR. FE(MDD-ps4) 0,404

Acc. #3144241 + VTS(MDD-ps4) 91,9 cm3

04/11/2016 29Hz AVIts ap4 30,4 cm2

St.ID 1272 19cm AVIts apical 30,4 cm2

LVIts apical 7,96 cm

2D

H3

Gan. 37

232dB/C5

D/2/0

MI 1,4

04/11/2016

Philips Healthcare

TIS 0,6

10:53:17 a.m

SE. #1

US

Im. #6

10:53:18 a.m.

Zoom: 104%

PS:

VOI:

WC: 128,00

WW: 256,00



ORIGINAL\PRIMARY\INTRACARDIAC\0001

BPM:





ACC Latin America
Conference 2017

CASE DISCUSSION






Heart Failure in Latin America-Etiology

First Author (Ref. #)	Country	Year	N	Mean Age (yrs)	Etiology									
					IDC	C'D	Iech	SH	Valv	Alco	Perip	Myo	EMF	Tox
Outpatient														
Felitas et al. (16)	Brazil	2005	1,220	45	37	20	17	14	5	4	2	1	<1%	<1%
Bocchi et al. (4)	Brazil	2008	350	50 and 52	10-17	21-16	22-28	22-18	3	8-4	NA	—	—	NA
Mendez et al. (31)	Mexico	2007	72	61	44	—	47	—	—	—	—	—	—	—
Silva et al. (38)	Brazil	2007	96	52	28.2	8.6	28.2	20.6	6.5	2.1	3.2	—	—	—
Ferrante et al. (37)	Argentina	2005	1,518	65	NA	NA	44.4	NA	—	NA	NA	—	—	—
Doval et al. (7)	Argentina	1994	516	50 and 52	19.5-23.0	10.5-8.1	38.3-39.6	NA	—	NA	NA	—	—	—
DHF														
Mangini et al. (17)	Brazil	2008	212	60	8	15	30	21	15	NA	NA	NA	NA	NA
Latado et al. (18)	Brazil	2006	299	69	3	9.7	49.2	25.8	11.7	—	—	0.7	—	—
Tavares et al. (25)	Brazil	2004	203	50 and 52	NA	NA	62-68	NA	NA	NA	NA	NA	NA	NA
Fairman et al. (19)	Argentina	2009	736	74	NA	4	21	76	20	NA	NA	NA	NA	NA
Perna et al. (6)	Argentina	1992-2004	2,974	65-70	1.3-13.8	1.3-8.4	27-38	18.2-32.3	16-22	1.0-5.4	—	—	—	—
Castro et al. (11)	Chile	2004	372	69	7.4	—	31.6	35	14.8	2.2	NA	NA	NA	NA
Bocchi et al. (20)	Brazil	2008	182	55	NA	21	34	NA	NA	NA	NA	NA	NA	NA
Barretto et al. (8)	Brazil	1998	903	53	25.8	6.2	32.6	7	22	NA	NA	NA	NA	NA
Rohde et al. (9)	Brazil	2005	143	73	NA	0.6	39	25	10	NA	NA	NA	NA	NA
McSwain et al. (28)	Antigua-Barbuda	1999	293	69	5	—	33	41	12	2	NA	NA	NA	NA
Thierier et al. (21)	Argentina	2002	400	68	5	4.3	28	21.8	17	NA	NA	NA	NA	NA
Rizzo et al. (22)	Argentina	2004	615	70	3.7	8.4	27.4	18.2	16.4	NA	NA	NA	NA	NA
Thierier et al. (23)	Argentina	2006	2,201	68	9.3	6	40.5	23.7	12	—	—	—	—	—



OPTIMIZE-HF 48612p, 8,7% with CCG




STICHES 10 year follow-up



ACC Latin America
Conference 2017


A Death from Any Cause (Primary Outcome)



No. at Risk

Medical therapy	602	532	487	435	404	357	315	274	248	164	82	37
CABG	610	532	487	460	432	392	356	312	286	205	103	42


B Death from Cardiovascular Causes



No. at Risk

Medical therapy	602	532	487	435	404	357	315	274	248	164	82	37
CABG	610	532	487	460	432	392	356	312	286	205	103	42

C Death from Any Cause or Cardiovascular Hospitalization




No. at Risk

Medical therapy	602	385	314	259	219	185	152	123	98	57	19
CABG	610	431	376	334	293	259	218	184	166	106	43

Myocardial viability and mortality


A Without Myocardial Viability



No. at Risk

Medical therapy	60	51	44	39	29	14	4
CABG	54	48	41	41	34	22	12

B With Myocardial Viability



No. at Risk

Medical therapy	243	219	206	179	146	94	51
CABG	244	213	203	192	148	94	51

C

Subgroup

Without viability

With viability

No.

114

487

Deaths

58

178


Hazard Ratio (95% CI)

0.70 (0.41–1.18)

0.86 (0.64–1.16)

P Value for Interaction

0.53





FREEDOM

Outcome	2 Years after Randomization		5 Years after Randomization		Patients with Event		P Value*
	PCI	CABG	PCI	CABG	PCI	CABG	
	number (percent)				number		
Primary composite†	121 (13.0)	108 (11.9)	200 (26.6)	146 (18.7)	205	147	0.005‡
Death from any cause	62 (6.7)	57 (6.3)	114 (16.3)	83 (10.9)	118	86	0.049
Myocardial infarction	62 (6.7)	42 (4.7)	98 (13.9)	48 (6.0)	99	48	<0.001
Stroke	14 (1.5)	24 (2.7)	20 (2.4)	37 (5.2)	22	37	0.03§
Cardiovascular death	9 (0.9)	12 (1.3)	73 (10.9)	52 (6.8)	75	55	0.12